PIRFENIVAS: Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies

Sponsor

Assistance Publique - Hôpitaux de Paris (Other)

Overall Status

Completed

CT.gov ID

NCT03385668

Collaborator

Roche Pharma AG (Industry)

Enrollment

Location

Arm

29.7

Actual Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to determine wether pirfenidone is safe and effective in the treatment of pulmonary fibrosis with anti-myeloperoxydase (MPO) antibodies or pulmonary fibrosis with anti-MPO associated vasculitis.

Condition or Disease	Intervention/Treatment	Phase
Pulmonary Fibrosis	Drug: Pirfenidone	Phase 2

Detailed Description

Pulmonary fibrosis can be associated with Anti-Neutrophil Cytoplasmic Antibody (ANCA) directed against MPO or with anti-MPO associated vasculitis, leading to increased disability and poor prognosis. The pathophysiology of this association remains unclear. Conventional therapies used for the treatment of vasculitis manifestations are often disappointing for the treatment of pulmonary fibrosis. The main cause of death in patients with anti-MPO ANCA associated vasculitis and associated pulmonary fibrosis is the progression of pulmonary fibrosis. No treatment has demonstrated efficacy to stabilize or improve pulmonary fibrosis associated with anti-MPO associated vasculitis.

Previous studies showed that Pirfenidone improves survival and pulmonary function in patients with idiopathic pulmonary fibrosis (IPF) and that Pirfenidone treatment is safe and well tolerated in IPF. Patients with anti-MPO associated vasculitis (or anti-MPO antibodies without vasculitis) and associated pulmonary fibrosis might benefit from the use of Pirfenidone. However, the efficacy and safety of pirfenidone in patients with anti-MPO associated vasculitis and associated pulmonary fibrosis has not been evaluated. This study was designed to assess the efficacy and safety of pirfenidone in patients with pulmonary fibrosis and anti-MPO ANCA associated vasculitis or anti-MPO antibodies without vasculitis.

Study Design

Study Type:

Interventional

Actual Enrollment :

7 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis."

Actual Study Start Date :

Jan 31, 2018

Actual Primary Completion Date :

Jul 24, 2020

Actual Study Completion Date :

Jul 24, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Pirfenidone All patients will receive Pirfenidone	Drug: Pirfenidone Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).

Arm

Intervention/Treatment

Experimental: Pirfenidone

All patients will receive Pirfenidone

Drug: Pirfenidone

Pirfenidone at a dose of 2403 mg/day for 50 weeks, after a 2 weeks period of titration (801 mg/day for one week then 1602 mg/day for one week).

Outcome Measures

Primary Outcome Measures

Treatment efficacy measured by the absolute change in percent predicted forced vital capacity (%FVC) [52 weeks]
Treatment efficacy at Week 52 measured by the absolute change from baseline to Week 52 in percent predicted forced vital capacity (%FVC) : Patients with progressive disease will be defined as absolute decline of 10% or more in %FVC. Missing values or death will be also considered as progressive. Patients with non-progressive disease will be defined as improvement or no decline in %FVC or a decline of %FVC<10%.

Secondary Outcome Measures

Adverse Events (AE) [56 weeks corresponding to 28 days after the last dose of study drug]
Safety parameters reported in the period from baseline to 28 days after the last dose of the study drug: Treatment-emergent AEs Treatment-emergent Serious Adverse Events (SAE) Treatment emergent Adverse Event of Special Interest (AESI) Treatment-emergent treatment-related AEs Treatment-emergent treatment-related SAEs Treatment emergent related AESIs AEs leading to early discontinuation of study treatment Treatment-emergent deaths Cause of death Treatment-emergent changes in clinical laboratory findings Vital signs
Treatment efficacy measured by the absolute change in percent predicted forced vital capacity (%FVC) [24 weeks]
Treatment efficacy at Week 24 measured by the absolute change from baseline to Week 24 in percent predicted forced vital capacity (%FVC) : Patients with progressive disease will be defined as absolute decline of 10% or more in %FVC. Missing values or death will be also considered as progressive. Patients with non-progressive disease will be defined as improvement or no decline in %FVC or a decline of %FVC<10%.
Relative change in in percent predicted forced vital capacity [52 weeks]
Relative change from baseline to Week 52 in percent predicted forced vital capacity (%FVC)
Absolute change in in percent predicted forced vital capacity [52 weeks]
Relative and absolute change from baseline to Week 52 in percent predicted forced vital capacity (%FVC)
Relative change in in percent predicted forced vital capacity [24 weeks]
Relative and absolute change from baseline to Week 24 in percent predicted forced vital capacity (%FVC)
Absolute change in in percent predicted forced vital capacity [24 weeks]
Relative and absolute change from baseline to Week 24 in percent predicted forced vital capacity (%FVC)
Six minute walk test (6MWT) distance [52 weeks]
Change from Baseline to Week 52 in the six minute walk test (6MWT) distance
Six minute walk test (6MWT) distance [24 weeks]
Change from Baseline to Week 24 in the six minute walk test (6MWT) distance
Carbon Monoxide Diffusing Capacity (%DLCO) [52 weeks]
Change from Baseline to Week 52 in the percent predicted Carbon Monoxide Diffusing Capacity (%DLCO)
Carbon Monoxide Diffusing Capacity (%DLCO) [24 weeks]
Change from Baseline to Week 24 in the percent predicted Carbon Monoxide Diffusing Capacity (%DLCO)
Progression-free survival [52 weeks]
Progression-free survival defined as the time to the first occurrence of any one of the following: a confirmed decrease of 10 percentage points or more in %FVC, a confirmed decrease of 15 percentage points or more in %DLCO, or death.
Dyspnea [52 weeks]
Change from Baseline to Week 52 in dyspnea as measured by the New York Heart Association classification, the modified Borg scale and by the Saint-George's Respiratory Questionnaire (SGRQ).
Chest CT-scan [52 weeks]
Change in Chest-CT scan abnormalities at Week 52 (evaluated after a centralized blinded review of the chest CT-scans).
Quality of Life assessed by the Health Assessment Questionnaire (HAQ) [52 weeks]
Quality of Life assessed by the Short Form-36 (SF-36) [52 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age > 18 years
Presence of anti-MPO antibody (ELISA) at inclusion or during pulmonary fibrosis follow-up and/or diagnosis of anti-MPO associated vasculitis according to the 2012 Revised International Chapel Hill Consensus Conference definitions
Definite or possible Usual Interstitial Pneumonia or Non Specific Interstitial Pneumonia based on high-resolution computed tomography
Presence of pulmonary fibrosis, defined as a range of 50 to 90% of the %FVC and a range of 30 to 90% of the %DLCO
Pulmonary fibrosis refractory (according to the investigator's judgment) to a conventional regimen used for anti-MPO associated vasculitis when a treatment against vasculitis has been used
Have the ability to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of research-related health information) and comply with the study protocol procedures (including required study visits)
Have affiliation with a mode of social security (profit our being entitled).

Exclusion Criteria:

Other type of systemic vasculitis;
Active vasculitis defined by Birmingham Vasculitis Activity Score >3 (BVAS) ;
Contraindication to Pirfenidone;
Unable to perform pulmonary function test (PFT);
Pregnancy or lactation. Women of childbearing capacity are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective contraception by practicing abstinence or by using an effective method of birth control from the date of consent through the end of the study : implants of levonorgestrel; injectable progesterone; any intrauterine device (IUD) with a documented failure rate of less than 1% per year; oral contraceptives (either combined or progesterone only); double barrier method (condom, cervical cap or diaphragm with spermicidal agent); transdermal contraceptive patch; male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for the female subject;
Any of the following liver function test criteria above specified limits: total bilirubin above 1,5 times the upper limit of normal (ULN), excluding patients with Gilbert's syndrome; aspartate (AST)/Glutamate Oxaloacétique Transaminase (SGOT) or alanine aminotransferase (ALT)/Glutamate Pyruvate Transaminase (SGPT), (AST/SGOT or ALT/SGPT) >3 × ULN; alkaline phosphatase >2.5 × ULN;
Creatinine clearance (CrCl<30) mL/min, calculated using the Cockcroft-Gault formula at screening
Current treatment with Nintedanib or past treatment with Nintedanib in the last 12 months;
Current treatment with Fluvoxamine or past treatment with Fluvoxamine in the last 28 days before screening
Prior use of Pirfenidone or known hypersensitivity to any of the components of study treatment;
Expected to receive a lung transplant within 1 year from randomization or, on a lung transplant waiting list at randomization;
Associated connective tissue disease (such as systemic sclerosis).;
Electrocardiogram (ECG), with a heart-rate-corrected QT interval (corrected using Fridericia's formula, QTcF) ≥ 500 ms at Screening, or a family or personal history of long QT syndrome;
Treatment with Cyclophosphamide in the last 3 months;
Current smoking or past smoking in the last 3 months.